{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:09:33Z","timestamp":1792696173627,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T00:00:00Z","timestamp":1471219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000765","name":"University College London (UCL)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s11940-016-0422-5","type":"journal-article","created":{"date-parts":[[2016,8,14]],"date-time":"2016-08-14T22:48:51Z","timestamp":1471214931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options"],"prefix":"10.1007","volume":"18","author":[{"given":"Ruth","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Rohrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huw R.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,15]]},"reference":[{"issue":"2","key":"422_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/jnnp.58.2.167","volume":"58","author":"SJ Collins","year":"1995","unstructured":"Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry. 1995;58(2):167\u201373. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=1073312&tool=pmcentrez&rendertype=abstract .","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"422_CR2","first-page":"85","volume":"8","author":"M Gold","year":"2012","unstructured":"Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat. 2012;8:85\u201393.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"422_CR3","first-page":"579","volume":"1999","author":"HR Morris","year":"2008","unstructured":"Morris HR, Wood NW, Lees AJ. Classic diseases revisited: progressive supranuclear palsy (Steele-Richardson-Olszewski disease). Postgrad Med J. 2008;1999:579\u201384.","journal-title":"Postgrad Med J"},{"key":"422_CR4","unstructured":"Maher ER, Smith EM, Lees AJ. Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). J Neurol Neurosurg Psychiatry. ENGLAND; 1985;48(12):1234\u20139."},{"key":"422_CR5","unstructured":"Barclay CL, Lang AE. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. ENGLAND; 1997;62(4):352\u20136."},{"key":"422_CR6","doi-asserted-by":"crossref","unstructured":"Neophytides A, Lieberman AN, Goldstein M, Gopinathan G, Leibowitz M, Bock J. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. 1982;(1981):261\u20133.","DOI":"10.1136\/jnnp.45.3.261"},{"issue":"6","key":"422_CR7","first-page":"427","volume":"54","author":"K Tawana","year":"2001","unstructured":"Tawana K, Ramsden DB. Progressive supranuclear palsy. Mol Pathol. 2001;54(6):427\u201334. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=1187134&tool=pmcentrez&rendertype=abstract .","journal-title":"Mol Pathol"},{"key":"422_CR8","doi-asserted-by":"crossref","unstructured":"Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. Elsevier Ltd; 2009;8(3):270\u20139. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1474442209700420 .","DOI":"10.1016\/S1474-4422(09)70042-0"},{"key":"422_CR9","doi-asserted-by":"crossref","unstructured":"Mahapatra R, Edwards M, Schott J, Bhatia K. Review: corticobasal degeneration. Lancet Neurol. 2004;3(December):736\u201343.","DOI":"10.1016\/S1474-4422(04)00936-6"},{"issue":"5","key":"422_CR10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496\u2013503. This review proposes new criteria for the clinical diagnosis of CBD based on consensus and a systematic literature review and describes four CBD phenotypes.","journal-title":"Neurology"},{"key":"422_CR11","unstructured":"Boeve BF, Maraganore DM, Parisi JE, Ahlskog JE, Graff-Radford N, Caselli RJ, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology. UNITED STATES; 1999;53(4):795\u2013800."},{"key":"422_CR12","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/WNL.56.12.1702","volume":"56","author":"H Houlden","year":"2001","unstructured":"Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001;56:1702\u20136.","journal-title":"Neurology"},{"issue":"3","key":"422_CR13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1468-1331.2008.02513.x","volume":"16","author":"AC Ludolph","year":"2009","unstructured":"Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, Burn DJ, et al. Tauopathies with Parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol. 2009;16(3):297\u2013309.","journal-title":"Eur J Neurol"},{"key":"422_CR14","doi-asserted-by":"crossref","unstructured":"Litvan I, Agid Y, Goetz C, Jankovic J, Wenning GK, Brandel JP, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study 141. Neurology. 1997;48:119\u201325.","DOI":"10.1212\/WNL.48.1.119"},{"issue":"Suppl 3","key":"422_CR15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1353-8020(08)70027-0","volume":"13","author":"PM Wadia","year":"2007","unstructured":"Wadia PM, Lang AE. The many faces of corticobasal degeneration. Parkinsonism Relat Disord. 2007;13 Suppl 3:336\u201340.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"422_CR16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/jnnp.64.2.184","volume":"64","author":"GK Wenning","year":"1998","unstructured":"Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry. 1998;64(2):184\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"422_CR17","doi-asserted-by":"crossref","unstructured":"Armstrong RA. Corticobasal Degeneration and Dementia [Internet]. Diet and nutrition in dementia and cognitive decline. Elsevier Inc.; 2015. 35\u201343 p. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780124078246000045 .","DOI":"10.1016\/B978-0-12-407824-6.00004-5"},{"key":"422_CR18","doi-asserted-by":"crossref","unstructured":"Marsili L, Suppa A, Berardelli A, Colosimo C. Therapeutic interventions in parkinsonism: Corticobasal degeneration. Parkinsonism Relat Disord. Elsevier Ltd; 2016;22:S96\u2013100. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802015003983 .","DOI":"10.1016\/j.parkreldis.2015.09.023"},{"key":"422_CR19","doi-asserted-by":"crossref","unstructured":"Hassan A, Whitwell JL, Josephs KA. The corticobasal syndrome\u2014Alzheimer\u2019 s disease conundrum. 2012;11(11):1569\u201378.","DOI":"10.1586\/ern.11.153"},{"issue":"7","key":"422_CR20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","volume":"13","author":"AL Boxer","year":"2014","unstructured":"Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, et al. Davunetide for progressive supranuclear palsy: a multicenter, randomized, double-blind, placebo controlled trial. Lancet Neurol. 2014;13(7):676\u201385. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4129545\/ .","journal-title":"Lancet Neurol"},{"key":"422_CR21","doi-asserted-by":"crossref","unstructured":"Tolosa E, Litvan I, Hoglinger GU, Burn D, Lees A, Andres M V, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. United States; 2014;29(4):470\u20138. These two papers (31 and 32) describe a double blind randomized placebo controlled trial of agents thought to play a role as modifying tau pathology in PSP.","DOI":"10.1002\/mds.25824"},{"key":"422_CR22","unstructured":"Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, et al. Lithium trial in Alzheimer\u2019s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. United States; 2009;70(6):922\u201331."},{"key":"422_CR23","doi-asserted-by":"crossref","unstructured":"Doble A. The pharmacology and mechanism of action of riluzole. Neurology. UNITED STATES; 1996;47(6 Suppl 4):S233\u201341.","DOI":"10.1212\/WNL.47.6_Suppl_4.233S"},{"issue":"Pt 1","key":"422_CR24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","volume":"132","author":"G Bensimon","year":"2009","unstructured":"Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009;132(Pt 1):156\u201371. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2638696&tool=pmcentrez&rendertype=abstract . This paper describes a double-blind, randomized, placebo-controlled trial of riluzole as a potential disease-modifying agent in PSP.","journal-title":"Brain"},{"issue":"8","key":"422_CR25","volume":"6","author":"CAM Payan","year":"2011","unstructured":"Payan CAM, Viallet F, Landwehrmeyer BG, Bonnet A-M, Borg M, Durif F, et al. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS\u2014Parkinson Plus Scale. PLoS One. 2011;6(8), e22293.","journal-title":"PLoS One"},{"key":"422_CR26","unstructured":"Seppi K, Peralta C, Diem-Zangerl A, Puschban Z, Mueller J, Poewe W, et al. Placebo-controlled trial of riluzole in multiple system atrophy. Eur J Neurol. England; 2006;13(10):1146\u20138."},{"issue":"3","key":"422_CR27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11940-013-0282-1","volume":"16","author":"MJ Armstrong","year":"2014","unstructured":"Armstrong MJ. Diagnosis and treatment of corticobasal degeneration. Curr Treat Options Neurol. 2014;16(3):282. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24469408 .","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"422_CR28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11940-012-0168-7","volume":"14","author":"T Karakaya","year":"2012","unstructured":"Karakaya T, Fu\u00dfer F, Prvulovic D, Hampel H. Treatment options for tauopathies. Curr Treat Options Neurol. 2012;14(2):126\u201336. Available from: http:\/\/link.springer.com\/10.1007\/s11940-012-0168-7 .","journal-title":"Curr Treat Options Neurol"},{"key":"422_CR29","doi-asserted-by":"crossref","unstructured":"Ling H, O\u2019Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. England; 2010;133(Pt 7):2045\u201357. This paper describes the variable clinical spectrum of CBD from a review of pathologically confirmed cases.","DOI":"10.1093\/brain\/awq123"},{"issue":"7","key":"422_CR30","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.55.7.957","volume":"55","author":"K Kompoliti","year":"1998","unstructured":"Kompoliti K, Goetz CG, Boeve BF, Maraganore DM, Ahlskog JE, Marsden CD, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol. 1998;55(7):957\u201361. Available from: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9678313 .","journal-title":"Arch Neurol"},{"issue":"9","key":"422_CR31","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s10072-015-2226-x","volume":"36","author":"HS Shehata","year":"2015","unstructured":"Shehata HS, Shalaby NM, Esmail EH, Fahmy E. Corticobasal degeneration: clinical characteristics and multidisciplinary therapeutic approach in 26 patients. Neurol Sci. 2015;36(9):1651\u20137.","journal-title":"Neurol Sci"},{"issue":"Cl","key":"422_CR32","first-page":"2116","volume":"47","author":"JD Parkes","year":"1971","unstructured":"Parkes JD, Knill-jones RP, Clements PJ. L-dopa and amantadine hydrochloride in extra-pyramidal disorders. Postgrad Med J. 1971;47(Cl):2116\u20139.","journal-title":"Postgrad Med J"},{"key":"422_CR33","first-page":"297","volume":"10","author":"L Riedl","year":"2014","unstructured":"Riedl L, Mackenzie IR, F\u00f6rstl H, Kurz A, Diehl-Schmid J. Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr Dis Treat. 2014;10:297\u2013310.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"422_CR34","unstructured":"Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. United States; 2007;15(1):84\u20137."},{"key":"422_CR35","unstructured":"Manoochehri M, Huey ED. Diagnosis and management of behavioral issues in frontotemporal dementia. Curr Neurol Neurosci Rep. United States; 2012;12(5):528\u201336."},{"issue":"5","key":"422_CR36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1586\/ern.11.6","volume":"11","author":"GA Kerchner","year":"2011","unstructured":"Kerchner GA, Tartaglia MC, Boxer A. Abhorring the vacuum: use of Alzheimer\u2019s disease medications in frontotemporal dementia. Expert Rev Neurother. 2011;11(5):709\u201317. Available from: http:\/\/eutils.ncbi.nlm.nih.gov\/entrez\/eutils\/elink.fcgi?dbfrom=pubmed&id=21728274&retmode=ref&cmd=prlinks\\npapers3:\/\/publication\/uuid\/6EC443BF-8BBC-4A02-9FB2-643874C72061 .","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"422_CR37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000113034","volume":"25","author":"A Kertesz","year":"2008","unstructured":"Kertesz A, Morlog D, Light M, Blair M, Davidson W, Jesso S, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25(2):178\u201385.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"422_CR38","doi-asserted-by":"crossref","unstructured":"Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. New Zealand; 2004;21(14):931\u20137.","DOI":"10.2165\/00002512-200421140-00003"},{"issue":"1","key":"422_CR39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1212\/01.wnl.0000191304.55196.4d","volume":"66","author":"ED Huey","year":"2006","unstructured":"Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66(1):17\u201322.","journal-title":"Neurology"},{"key":"422_CR40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1744-859X-6-15","volume":"6","author":"ND Weder","year":"2007","unstructured":"Weder ND, Aziz R, Wilkins K, Tampi RR. Frontotemporal dementias: a review. Ann General Psychiatry. 2007;6:15.","journal-title":"Ann General Psychiatry"},{"issue":"5","key":"422_CR41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/153331750201700504","volume":"17","author":"TW Chow","year":"2002","unstructured":"Chow TW. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2002;17(5):267\u201372. Available from: http:\/\/aja.sagepub.com\/cgi\/doi\/10.1177\/153331750201700504 .","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"1","key":"422_CR42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000067021","volume":"49","author":"R Moretti","year":"2003","unstructured":"Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms: a randomized, controlled, open 14-month study. Eur Neurol. 2003;49(1):13\u20139.","journal-title":"Eur Neurol"},{"issue":"4","key":"422_CR43","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00213-003-1686-5","volume":"172","author":"JB Deakin","year":"2004","unstructured":"Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berlin). 2004;172(4):400\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14666399 .","journal-title":"Psychopharmacology (Berlin)"},{"issue":"9","key":"422_CR44","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/JGP.0b013e31823033f3","volume":"20","author":"N Herrmann","year":"2012","unstructured":"Herrmann N, Black SE, Chow T, Cappell J, Tang-Wai DF, Lanct\u00f4t KL. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry. 2012;20(9):789\u201397. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1064748112619964 .","journal-title":"Am J Geriatr Psychiatry"},{"issue":"7","key":"422_CR45","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00415-004-0483-3","volume":"251","author":"A Schrag","year":"2004","unstructured":"Schrag A. Psychiatric aspects of Parkinson\u2019s disease. J Neurol. 2004;251(7):795\u2013804. Available from: http:\/\/link.springer.com\/10.1007\/s00415-004-0483-3 .","journal-title":"J Neurol"},{"issue":"2","key":"422_CR46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1472-8206.2005.00317.x","volume":"19","author":"HA Hanagasi","year":"2005","unstructured":"Hanagasi HA, Emre M. Treatment of behavioural symptoms and dementia in Parkinson\u2019s disease. Fundam Clin Pharmacol. 2005;19(2):133\u201346.","journal-title":"Fundam Clin Pharmacol"},{"key":"422_CR47","doi-asserted-by":"crossref","unstructured":"Lebert F. Behavioral benefits of trazodone are sustained for the long term in frontotemporal dementia. Therapy. 2006;3(1):93\u20136.","DOI":"10.2217\/14750708.3.1.93"},{"key":"422_CR48","unstructured":"Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. Switzerland; 2004;17(4):355\u20139."},{"issue":"4","key":"422_CR49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/(SICI)1099-1077(199906)14:4<279::AID-HUP89>3.0.CO;2-1","volume":"14","author":"F Lebert","year":"1999","unstructured":"Lebert F, Pasquier F. Trazodone in the treatment of behaviour in frontotemporal dementia. Hum Psychopharmacol Clin Exp. 1999;14(4):279\u201381.","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"8","key":"422_CR50","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archneur.55.8.1099","volume":"55","author":"K Kompoliti","year":"1998","unstructured":"Kompoliti K, Goetz CG, Litvan I, Jellinger K, Verny M. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol. 1998;55(8):1099\u2013102.","journal-title":"Arch Neurol"},{"issue":"4","key":"422_CR51","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00002826-199308000-00006","volume":"16","author":"KA Nieforth","year":"1993","unstructured":"Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol. 1993;16(4):338\u201346. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8374914 .","journal-title":"Clin Neuropharmacol"},{"key":"422_CR52","unstructured":"Furlan JC, Henri-Bhargava A, Freedman M. Clomipramine in the treatment of compulsive behavior in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. United States; 2014;28(1):95\u20138."},{"issue":"2B","key":"422_CR53","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1590\/S0004-282X2009000300007","volume":"67","author":"ALDS Werneck","year":"2009","unstructured":"Werneck ALDS, Rosso AL, Vincent MB. The use of an antagonist 5-HT2a\/c for depression and motor function in Parkinson\u2019 disease. Arq Neuropsiquiatr. 2009;67(2B):407\u201312. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19623435 .","journal-title":"Arq Neuropsiquiatr"},{"key":"422_CR54","doi-asserted-by":"publisher","unstructured":"Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med. Massachusetts Medical Society; 1999;341(7):543\u20134. 10.1056\/NEJM199908123410721 .","DOI":"10.1056\/NEJM199908123410721"},{"key":"422_CR55","doi-asserted-by":"crossref","unstructured":"Chang AY, Weirich E. Case report trial of zolpidem, eszopiclone, and other GABA agonists in a patient with progressive supranuclear palsy. Hindawi Publishing Corporation; 2014.","DOI":"10.1155\/2014\/107064"},{"key":"422_CR56","doi-asserted-by":"publisher","unstructured":"Cotter C, Armytage T, Crimmins D. The use of zolpidem in the treatment of progressive supranuclear palsy. J Clin Neurosci. Elsevier Ltd; 2010;17(3):385\u20136. 10.1016\/j.jocn.2009.05.038 .","DOI":"10.1016\/j.jocn.2009.05.038"},{"issue":"1","key":"422_CR57","doi-asserted-by":"crossref","first-page":"28","DOI":"10.14802\/jmd.14007","volume":"7","author":"JW Cho","year":"2014","unstructured":"Cho JW, Lee JH. Suppression of myoclonus in corticobasal degeneration by levetiracetam. J Mov Disord. 2014;7(1):28\u201330. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=4051726&tool=pmcentrez&rendertype=abstract .","journal-title":"J Mov Disord"},{"key":"422_CR58","doi-asserted-by":"crossref","unstructured":"Arbouw MEL, Movig KLL, Koopmann M, Poels PJE, Guchelaar H-J, Egberts TCG, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology. United States; 2010;74(15):1203\u20137.","DOI":"10.1212\/WNL.0b013e3181d8c1b7"},{"key":"422_CR59","doi-asserted-by":"crossref","unstructured":"Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord. United States; 2011;26 Suppl 3:S42\u201380.","DOI":"10.1002\/mds.23884"},{"key":"422_CR60","unstructured":"Gomez-Caravaca MT, Caceres-Redondo MT, Huertas-Fernandez I, Vargas-Gonzalez L, Carrillo F, Carballo M, et al. The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. Italy; 2015;36(2):275\u20139."},{"key":"422_CR61","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1002\/mds.20545","volume":"20 Suppl 1","author":"AE Lang","year":"2005","unstructured":"Lang AE. Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord. 2005;20 Suppl 1:S83\u201391. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16092096 .","journal-title":"Mov Disord"},{"issue":"6","key":"422_CR62","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/jnnp.60.6.704","volume":"60","author":"J Jankovic","year":"1996","unstructured":"Jankovic J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J Neurol Neurosurg Psychiatry. 1996;60(6):704. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=1073973&tool=pmcentrez&rendertype=abstract .","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"422_CR63","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0003-9993(97)90169-6","volume":"78","author":"F Piccione","year":"1997","unstructured":"Piccione F, Mancini E, Tonin P, Bizzarini M. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med Rehabil. 1997;78(5):525\u20139. Available from: http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=1997150703 .","journal-title":"Arch Phys Med Rehabil"},{"key":"422_CR64","unstructured":"Goldberg LS, Altman KW. The role of gastrostomy tube placement in advanced dementia with dysphagia: a critical review. Clin Interv Aging. New Zealand; 2014;9:1733\u20139."},{"issue":"1","key":"422_CR65","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000341602","volume":"2","author":"L Farrajota","year":"2012","unstructured":"Farrajota L, Maruta C, Maroco J, Martins IP, Guerreiro M, de Mendon\u00e7a A. Speech therapy in primary progressive aphasia: a pilot study. Dement Geriatr Cogn Dis Extra. 2012;2(1):321\u201331. Available from: http:\/\/www.karger.com\/doi\/10.1159\/000341602 .","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"422_CR66","doi-asserted-by":"crossref","unstructured":"Henry ML, Rising K, DeMarco AT, Miller BL, Gorno-Tempini ML, Beeson PM. Examining the value of lexical retrieval treatment in primary progressive aphasia: two positive cases. Brain Lang. Elsevier Inc.; 2013;127(2):145\u201356. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093934X13001168 .","DOI":"10.1016\/j.bandl.2013.05.018"},{"issue":"7\u20138","key":"422_CR67","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1080\/02687030701820055","volume":"22","author":"ML Henry","year":"2008","unstructured":"Henry ML, Beeson PM, Rapcsak SZ. Treatment for lexical retrieval in progressive aphasia. Aphasiology. 2008;22(7\u20138):826\u201338.","journal-title":"Aphasiology"},{"issue":"3","key":"422_CR68","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s12031-011-9579-2","volume":"45","author":"PM Beeson","year":"2011","unstructured":"Beeson PM, King RM, Bonakdarpour B, Henry ML, Cho H, Rapcsak SZ. Positive effects of language treatment for the logopenic variant of primary progressive aphasia. J Mol Neurosci. 2011;45(3):724\u201336.","journal-title":"J Mol Neurosci"},{"issue":"1\u20132","key":"422_CR69","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1155\/2013\/824302","volume":"26","author":"ML Henry","year":"2013","unstructured":"Henry ML, Meese MV, Truong S, Babiak MC, Miller BL, Gorno-Tempini ML. Treatment for apraxia of speech in nonfluent variant primary progressive aphasia. Behav Neurol. 2013;26(1\u20132):77\u201388.","journal-title":"Behav Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0422-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-016-0422-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0422-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T10:59:50Z","timestamp":1568285990000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-016-0422-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,15]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["422"],"URL":"https:\/\/doi.org\/10.1007\/s11940-016-0422-5","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,15]]},"article-number":"42"}}